This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Relationship Disclosure: Semaglutide Watchdog and its publisher, US Peptides Partners LLC, have no ownership, affiliate, referral, advertising, management, reviewer, or other material financial relationship with certain providers listed on this website. All providers are evaluated using the same documented evidence, pricing, and verification methodology, regardless of relationship status.
How to verify the pharmacy behind your GLP-1
The telehealth company arranges your consultation. The pharmacy makes the thing you inject into your body.
The short version
The pharmacy matters more than the brand on the website. Seven questions, and what the answers tell you.
The analysis
Questions to ask about the pharmacy
- Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
- Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
- In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
- What is the exact salt form and concentration? Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
- Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
- Will you provide a certificate of analysis?
- Has the pharmacy received any FDA warning letter or state board action?
Reported harms — FDA adverse-event dataAs of February 28, 2025, the FDA had received more than 1,700 adverse-event reports involving compounded semaglutide and tirzepatide (FDA, as of 21 May 2026 — more than double the 775 reported in February 2025). A recurring cause is dosing error: patients or clinicians measuring the wrong volume from a multi-dose vial, sometimes by a factor of ten. Brand auto-injectors and single-dose vials remove that failure mode; a compounded multi-dose vial reintroduces it.
Semaglutide salts are not semaglutideSome compounded products use semaglutide salts — semaglutide sodium or semaglutide acetate. These are not the same active ingredient as the semaglutide base in Wegovy and Ozempic, and the FDA has stated they are not approved for use in compounding. A program that will not state its exact salt form and concentration cannot be evaluated on safety.
How to verify any of this yourself
- Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
- Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
- Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
- Ask what the highest dose costs. By email or chat, so you have it in writing.
- Ask about early cancellation before you commit to a plan longer than a month.
- Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.
What to do about it
Three practical steps follow from everything above.
- Check your insurance first. A covered brand prescription with a manufacturer savings card can cost roughly $25 a month, which beats every cash option discussed here.
- Then price the manufacturer directly. LillyDirect and NovoCare sell brand GLP-1s for $149-$449. Several telehealth platforms resell the identical drugs at four to eleven times that.
- Then, and only then, compare compounded programmes — on their ongoing total cost, medication plus any mandatory membership, at the dose you expect to maintain.
Limitations of this analysis
Frequently asked questions
What is the single most useful thing to check?
How current is this?
Do you earn commission?
Update history
| Date | What changed |
|---|---|
| July 12, 2026 | Brand pricing re-verified. |
| July 6, 2026 | Provider dataset refreshed. |
Sources
- U.S. Food and Drug Administration — labels, compounding guidance, adverse-event reporting.
- Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare) published self-pay pricing.
- NexLife published program pages, transcribed July 11, 2026.
- Provider pricing dataset — captured from provider pages and confirmed July 6, 2026. Verified.
- Our pricing-verification methodology and source policy.
Registration is per-facility, not per-company: one company can operate both. Source: FDCA sections 503A and 503B; FDA compounding guidance.
The regulatory reality every provider glosses over
| Date | What happened | Why it matters to you |
|---|---|---|
| 15 Dec 2022 | Tirzepatide added to the FDA drug shortage list. | The shortage exception opens. This is what created the compounded market. |
| 2 Oct 2024 | FDA declares the tirzepatide shortage RESOLVED. | The legal basis for compounding tirzepatide as an 'essentially a copy' drug begins to close. |
| 19 Dec 2024 | FDA reaffirms resolution in a declaratory order. | Sets a 60-day (503A) and 90-day (503B) transition. |
| 18 Feb 2025 | 503A enforcement discretion for tirzepatide ENDS. | State-licensed pharmacies must stop compounding tirzepatide copies. |
| 19 Mar 2025 | 503B enforcement discretion for tirzepatide ENDS. | Outsourcing facilities must stop too. |
| 24 Apr / 7 May 2025 | Courts deny the Outsourcing Facilities Association injunction. | OFA v. FDA, N.D. Tex. The FDA's determination stands. |
| 30 Apr 2026 | FDA proposes excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list. | Finding: no clinical need. Comment period closed 29 Jun 2026. |
The rule that governs everything: “essentially a copy”
Why every provider suddenly sells “personalized” and “microdose” doses
Registration is per-facility, not per-company. Source: FDCA §503A and §503B; FDA compounding guidance.
The phrase that should end your evaluation of a providerThere is no such thing as an “FDA-approved pharmacy.” The phrase appears constantly in this industry's marketing and it is meaningless.
A pharmacy is either state-licensed (503A) or an FDA-registered outsourcing facility (503B). Registered is not approved. Neither status makes the compounded drug it produces FDA-approved, and the FDA has specifically warned telehealth companies against implying otherwise.
If you see ‘FDA-approved pharmacy’, ‘FDA-licensed pharmacy’, or ‘generic Zepbound’ on a provider's site, treat everything else on that site with suspicion. It tells you they are either careless with regulatory language or willing to mislead — and you cannot tell which.
A pharmacy is either state-licensed (503A) or an FDA-registered outsourcing facility (503B). Registered is not approved. Neither status makes the compounded drug it produces FDA-approved, and the FDA has specifically warned telehealth companies against implying otherwise.
If you see ‘FDA-approved pharmacy’, ‘FDA-licensed pharmacy’, or ‘generic Zepbound’ on a provider's site, treat everything else on that site with suspicion. It tells you they are either careless with regulatory language or willing to mislead — and you cannot tell which.
The seven-question pharmacy verification checklist
- Which specific pharmacy will fill my prescription? Not “our network of licensed pharmacies” — the name of the facility.
- Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and registration is per-facility, not per-company — one company can operate both.
- In which state is it licensed, and can I look up the licence? State boards of pharmacy publish searchable licensee databases. Use them.
- What is the exact salt form and concentration?
- Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself — the most common source of the reported adverse events above.
- Will you provide a certificate of analysis? And note the limitation: a CoA reflects the batch that was tested, not necessarily the vial in your hand.
- Has the pharmacy received any FDA warning letter or state board action?
Adverse events: the figure almost every site gets wrong
Source: FDA GLP-1 webpage, reporting 1,700+ adverse events associated with compounded semaglutide and tirzepatide as of May 21, 2026 — against the 775 total, Feb 2025 figures from February 2025 that almost every comparison site is still quoting. Reports are voluntary and do not establish causation, but the trend is the point.
1,700+ — not 775. We were wrong too, and we have corrected it.The adverse-event figure you have read elsewhere is out of date. Nearly every comparison site — and this site, until we rechecked — quotes 1,700+ reports for compounded semaglutide and 320 for compounded tirzepatide. Those are February 2025 figures.
As of 21 May 2026, the FDA reports having received more than 1,700 adverse events associated with compounded semaglutide and tirzepatide. That is more than double the figure still in circulation, in roughly fifteen months.
Adverse-event reports are voluntary, are not adjudicated, and do not by themselves establish causation. That caveat is real and we will not drop it. But a site that quotes the 2025 number in mid-2026 is not being cautious — it is being out of date, and in a direction that flatters the product it is paid to sell.
As of 21 May 2026, the FDA reports having received more than 1,700 adverse events associated with compounded semaglutide and tirzepatide. That is more than double the figure still in circulation, in roughly fifteen months.
Adverse-event reports are voluntary, are not adjudicated, and do not by themselves establish causation. That caveat is real and we will not drop it. But a site that quotes the 2025 number in mid-2026 is not being cautious — it is being out of date, and in a direction that flatters the product it is paid to sell.
Tirzepatide + B12 is not tirzepatideA March 2026 study identified a previously unknown tirzepatide–B12 adduct in mass-compounded tirzepatide formulated with vitamin B12. An adduct is a new chemical entity formed when two molecules combine. This one does not exist in FDA-approved tirzepatide, and its safety has not been characterised.
This matters far beyond one study, because it exposes the flaw in the whole ‘personalized dosing’ defence. Adding B12 was one of the commonest ways compounders argued their product was not “essentially a copy” of the approved drug — a clinical difference that kept them inside the law. The finding shows that the additive did not merely differentiate the product on paper. It chemically changed it, into something nobody has tested in a human being.
What to do: if you are taking a compounded tirzepatide that contains B12 — and many do, often marketed as ‘tirzepatide + B12’ or ‘with methylcobalamin’ — ask your provider and your pharmacy, in writing, whether they have tested for adduct formation. Most will not have. That answer is itself information.
This matters far beyond one study, because it exposes the flaw in the whole ‘personalized dosing’ defence. Adding B12 was one of the commonest ways compounders argued their product was not “essentially a copy” of the approved drug — a clinical difference that kept them inside the law. The finding shows that the additive did not merely differentiate the product on paper. It chemically changed it, into something nobody has tested in a human being.
What to do: if you are taking a compounded tirzepatide that contains B12 — and many do, often marketed as ‘tirzepatide + B12’ or ‘with methylcobalamin’ — ask your provider and your pharmacy, in writing, whether they have tested for adduct formation. Most will not have. That answer is itself information.
FDA: affordability is not a clinical needThe FDA has explicitly rejected the argument that this entire industry rests on.
In the 30 April 2026 Federal Register notice (docket 2026-08552), the agency stated that there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk — and went out of its way to clarify that supply and affordability are not what the statute means by clinical need.
In plain terms: there are FDA-approved products; they work; patients can be treated with them. Whether a patient can afford them is a different problem, with a different set of policy tools.
That single sentence does enormous work. Every compounded-GLP-1 marketing page in America is, at bottom, an affordability argument. The agency has now said, on the record, that affordability is not a legal basis for compounding these drugs. If you are choosing a compounded programme because it is cheaper, you should know that the regulator has explicitly said that reason does not count.
In the 30 April 2026 Federal Register notice (docket 2026-08552), the agency stated that there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk — and went out of its way to clarify that supply and affordability are not what the statute means by clinical need.
In plain terms: there are FDA-approved products; they work; patients can be treated with them. Whether a patient can afford them is a different problem, with a different set of policy tools.
That single sentence does enormous work. Every compounded-GLP-1 marketing page in America is, at bottom, an affordability argument. The agency has now said, on the record, that affordability is not a legal basis for compounding these drugs. If you are choosing a compounded programme because it is cheaper, you should know that the regulator has explicitly said that reason does not count.